PT  - JOURNAL ARTICLE
AU  - Chumpol Theeraladanon
AU  - Ukihide Tateishi
AU  - Masaaki Shiina
AU  - Ryogo Minamimoto
AU  - Hisashi Endo
AU  - Takashi Oka
AU  - Nobukazu Takahashi
AU  - Tomio Inoue
TI  - Synthesis and labeling of a novel EGFR and HER-2 tyrosine kinase inhibitor containing 4-anilinoquinoline-3-carbonitrile nucleus
DP  - 2009 May 01
TA  - Journal of Nuclear Medicine
PG  - 1116--1116
VI  - 50
IP  - supplement 2
4099  - http://jnm.snmjournals.org/content/50/supplement_2/1116.short
4100  - http://jnm.snmjournals.org/content/50/supplement_2/1116.full
SO  - J Nucl Med2009 May 01; 50
AB  - 1116 Learning Objectives Since our novel EGFR inhibitor containing quinoline nucleus, YCU07, was previously reported. We currently have developed a more potent EGFR inhibitor according to recent studies of 4-anilinoquinoline-3-carbonitrile that function as irreversible EGFR and HER-2 tyrosine kinase inhibitory activity. To evaluate its specificity at both EGFR and HER-2 binding site, [6,7-dimethoxyethoxy]-quinolin-3-carbonitrile-4-yl]-(3-ethynylphenyl)-amine (YCU09) was synthesized and labeled with 68Ga using glutamic acid polypeptide (GAP) as chelating agent. Synthesis of YCU09 was started with 2-acetyl-4,5-dimethoxyaniline then utilized Ring Closing Metathesis (RCM) and Mukaiyama-Aldol reaction as key steps for construction of 4-anilinoquinoline-3-carbonitrile nucleus. YCU09 was conjugated to glutamic acid polypeptide (GAP) and in-house labeled with 68Ga. Synthesis of YCU09 was accomplished in 8 Steps. This methodology could be applied for assemble many substituted groups on 4-anilinoquinoline-3-carbonitrile synthesis. An efficient and practical synthetic route of YCU09 was established. It was conjugated to GAP and successfully labeled with 68Ga. Summary: An efficient and practical synthetic route of YCU09 was established. It was conjugated to GAP and successfully labeled with 68Ga.